Advertisement

Mineralys Therapeutics, Inc. MLYS

Set alert

Price alert · MLYS

All alert types
18.18 USD -3.06 -14.41%

At close · Oct 30

18.29 +0.11 +0.61%

After hours · Oct 30, 7:18 PM ET

Bid
18.15 × 2
Ask
18.16 × 1
18.11 Day range 20.99
18.18 52-week range 47.33
YTD
-49.90%
1 year
-55.79%
Open
20.99
Prev close
21.24
Mkt cap
1.60B
Vol
3.98M
Avg vol
1.22M
EPS
-4.22
P/E
0.00
Div yield
0.00%
More statistics
Low
18.11
High
20.99
Forward P/E
-7.40
Beta
0.69
Short ratio
4.98
Inst. own
117.50%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
24.93
200-d avg
27.07
1y target
46.33

2Y chart

Chart tools
Interval

Events in this range
  • Aug 12, 2025Earnings: -0.66; estimate -0.78; surprise 15.38%
  • Nov 10, 2025Earnings: -0.52; estimate -0.66; surprise 21.21%
  • Nov 12, 2025Rating: HC Wainwright & Co. · Buy → Buy
  • Dec 19, 2025Rating: Stifel · Buy → Buy
  • Mar 12, 2026Earnings: -0.4; estimate -0.51625; surprise 22.52%
  • Mar 13, 2026Rating: B of A Securities · Buy → Buy
  • Apr 27, 2026Rating: TD Cowen · — → Buy
  • May 6, 2026Earnings: -0.47; estimate -0.51; surprise 7.84%
  • Aug 12, 2026Earnings: -2.85; estimate -0.54857; surprise -419.53%
  • Oct 12, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Oct 12, 2026Rating: UBS · — → Neutral
Signals (110)
NameDateAgo
RSI: OversoldOct 30, 20261 day ago
MACD: Buy SignalOct 22, 20261 week ago
RSI: OversoldOct 6, 20263 weeks ago
SMA: BearishSep 23, 20261 month ago
SMA: BearishSep 23, 20261 month ago
MACD: Sell SignalSep 23, 20261 month ago
SMA: BullishSep 22, 20261 month ago
MACD: Buy SignalSep 22, 20261 month ago
MACD: Sell SignalSep 18, 20261 month ago
SMA: BearishSep 10, 20261 month ago
SMA: BullishSep 8, 20261 month ago
RSI: OverboughtSep 8, 20261 month ago
SMA: BullishSep 2, 20261 month ago
MACD: Buy SignalSep 2, 20261 month ago
SMA: BearishAug 20, 20262 months ago
SMA: BullishAug 18, 20262 months ago
MACD: Sell SignalAug 14, 20262 months ago
SMA: BearishAug 13, 20262 months ago
MACD: Buy SignalAug 7, 20262 months ago
SMA: BullishAug 5, 20262 months ago
SMA: BearishJul 28, 20263 months ago
SMA: BullishJul 27, 20263 months ago
SMA: BearishJul 22, 20263 months ago
SMA: BullishJul 21, 20263 months ago
MACD: Sell SignalJul 16, 20263 months ago
SMA: BearishJul 14, 20263 months ago
SMA: BullishJul 2, 20264 months ago
MACD: Buy SignalJun 23, 20264 months ago
SMA: BearishJun 3, 20265 months ago
MACD: Sell SignalJun 3, 20265 months ago
MACD: Buy SignalMay 22, 20265 months ago
SMA: BullishMay 20, 20265 months ago
SMA: BearishMay 18, 20265 months ago
SMA: BullishMay 14, 20265 months ago
SMA: BearishMay 13, 20265 months ago
MACD: Sell SignalMay 13, 20265 months ago
MACD: Buy SignalMay 4, 20266 months ago
SMA: BullishMay 1, 20266 months ago
SMA: BearishApr 27, 20266 months ago
MACD: Sell SignalApr 27, 20266 months ago
SMA: BearishApr 20, 20266 months ago
SMA: BullishApr 15, 20266 months ago
SMA: BullishApr 15, 20266 months ago
SMA: BearishApr 8, 20266 months ago
SMA: BullishApr 6, 20266 months ago
MACD: Buy SignalMar 31, 20267 months ago
RSI: OversoldMar 24, 20267 months ago
RSI: OversoldMar 18, 20267 months ago
MACD: Sell SignalMar 13, 20267 months ago
MACD: Buy SignalMar 10, 20267 months ago
MACD: Sell SignalMar 6, 20267 months ago
SMA: BearishMar 5, 20268 months ago
SMA: BullishFeb 23, 20268 months ago
MACD: Buy SignalFeb 23, 20268 months ago
SMA: BearishFeb 20, 20268 months ago
SMA: BullishFeb 17, 20268 months ago
SMA: BearishFeb 13, 20268 months ago
MACD: Sell SignalFeb 12, 20268 months ago
MACD: Buy SignalFeb 9, 20268 months ago
RSI: OversoldFeb 5, 20268 months ago
MACD: Sell SignalFeb 4, 20268 months ago
MACD: Buy SignalFeb 3, 20269 months ago
MACD: Sell SignalFeb 2, 20269 months ago
MACD: Buy SignalJan 22, 20269 months ago
RSI: OversoldJan 15, 20269 months ago
RSI: OversoldJan 12, 20269 months ago
RSI: OversoldJan 8, 20269 months ago
MACD: Sell SignalJan 7, 20269 months ago
MACD: Buy SignalJan 6, 20269 months ago
MACD: Sell SignalJan 5, 20269 months ago
MACD: Buy SignalDec 23, 202510 months ago
SMA: BearishDec 1, 202511 months ago
MACD: Sell SignalNov 19, 202511 months ago
MACD: Buy SignalNov 11, 202511 months ago
SMA: BullishNov 10, 202511 months ago
SMA: BearishNov 6, 202511 months ago
RSI: OverboughtOct 10, 20251 year ago
RSI: OverboughtOct 1, 20251 year ago
MACD: Sell SignalSep 23, 20251 year ago
RSI: OverboughtSep 2, 20251 year ago
SMA: BullishAug 15, 20251 year ago
MACD: Buy SignalAug 14, 20251 year ago
MACD: Sell SignalAug 4, 20251 year ago
MACD: Buy SignalJul 30, 20251 year ago
MACD: Sell SignalJul 28, 20251 year ago
MACD: Buy SignalJul 25, 20251 year ago
MACD: Sell SignalJul 22, 20251 year ago
SMA: BearishJul 15, 20251 year ago
SMA: BullishJul 14, 20251 year ago
MACD: Buy SignalJul 8, 20251 year ago
MACD: Sell SignalJul 7, 20251 year ago
MACD: Buy SignalJul 3, 20251 year ago
SMA: BearishJun 13, 20251 year ago
MACD: Sell SignalMay 29, 20251 year ago
MACD: Buy SignalApr 29, 20251 year ago
SMA: BullishApr 9, 20251 year ago
SMA: BearishApr 8, 20251 year ago
MACD: Sell SignalMar 28, 20251 year ago
RSI: OverboughtMar 25, 20251 year ago
RSI: OverboughtMar 18, 20251 year ago
RSI: OverboughtMar 10, 20251 year ago
SMA: BullishMar 6, 20251 year ago
MACD: Buy SignalMar 4, 20251 year ago
MACD: Sell SignalMar 3, 20251 year ago
MACD: Buy SignalFeb 27, 20251 year ago
MACD: Sell SignalFeb 24, 20251 year ago
MACD: Buy SignalJan 28, 20251 year ago
RSI: OversoldJan 13, 20251 year ago
MACD: Sell SignalJan 8, 20251 year ago
MACD: Buy SignalDec 24, 20241 year ago

Key statistics

Market cap
1.60B
Enterprise value
1.31B
Trailing P/E
0.00
Forward P/E
-7.40
PEG ratio
0.00
Price / sales
0.00
Price / book
2.92
EPS (TTM)
-4.22
Beta
0.69
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-203.46M
Total cash
661.41M
Total debt
97.62M
Return on equity
-80.88%
Shares outstanding
88.16M
Short % of float
10.07%
50-day average
24.93
200-day average
27.07

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 46.33 +154.9% upside
Target (low)
29.00
Target (mean)
46.33
Target (high)
56.00
Ratings (0m) 11 9 buy · 2 hold · 0 sell
  • Strong buy0
  • Buy9
  • Hold2
  • Sell0
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate -0.53938.

Earnings history

Financials — quick view

All financials
MLYS Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MLYS Net income — quarterly -241.07M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MLYS EPS — quarterly -2.85
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MLYS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 30, 2026-0.5548———
Aug 12, 2026Jun 30, 2026-0.54857-2.85-2.30-419.53%
May 6, 2026Mar 31, 2026-0.51-0.47+0.04+7.84%
Mar 12, 2026Dec 31, 2025-0.51625-0.40+0.12+22.52%
Nov 10, 2025Sep 30, 2025-0.66-0.52+0.14+21.21%
Aug 12, 2025Jun 30, 2025-0.78-0.66+0.12+15.38%

Upgrades / downgrades

MLYS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 12, 2026UBSinit—Neutral
Oct 12, 2026HC Wainwright & Co.reitBuyBuy
Apr 27, 2026TD Coweninit—Buy
Mar 13, 2026B of A SecuritiesmainBuyBuy
Dec 19, 2025StifelmainBuyBuy
Nov 12, 2025HC Wainwright & Co.mainBuyBuy

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MLYS — it syncs with the Stock Master app.

Insider holders

MLYS insider holders
InsiderRelationLatest transactionDateShares held
AKKARAJU SRINIVASDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Feb 18, 20265,877,220
CONGLETON JONChief Executive OfficerSaleJul 12, 2026603,621
FERGUSON JAMES J. IIIOfficerStock Award(Grant)Aug 9, 2026102,400
KARYDAS DAPHNEDirectorConversion of Exercise of derivative securitySep 14, 20266,200
LEVY ADAM SCOTTChief Financial OfficerStock Award(Grant)Feb 18, 202648,538
RA CAPITAL MANAGEMENT, L.P.Beneficial Owner of more than 10% of a Class of SecurityPurchaseMar 29, 20260

Institution ownership

MLYS institution ownership
Holder% heldSharesValueReported
Catalys Pacific, LLC8.94%7,903,838143.69MJun 29, 2026
RA Capital Management, L.P.8.70%7,692,750139.85MJun 29, 2026
Blackrock Inc.6.66%5,887,038107.03MJun 29, 2026
Samsara BioCapital, LLC6.64%5,871,018106.74MJun 29, 2026
FMR, LLC5.10%4,511,68982.02MJun 29, 2026
State Street Corporation4.68%4,141,63675.29MJun 29, 2026

Fund ownership

MLYS fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc2.83%2,502,85445.50MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.23%1,968,12435.78MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.79%1,584,49328.81MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.66%1,468,68926.70MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio1.33%1,180,00021.45MAug 30, 2026
T. Rowe Price New Horizons Fund, Inc.0.94%828,59715.06MJun 29, 2026
Advertisement